These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 21920001

  • 1. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL.
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Scand J Gastroenterol; 2008 Dec; 43(10):1202-11. PubMed ID: 18618371
    [Abstract] [Full Text] [Related]

  • 3. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K.
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [Abstract] [Full Text] [Related]

  • 4. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q, Zhang Y, Chen F, Zuo X, Li Y.
    BMC Gastroenterol; 2018 Jan 08; 18(1):5. PubMed ID: 29310568
    [Abstract] [Full Text] [Related]

  • 5. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun 08; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 6. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.
    Am J Gastroenterol; 2005 Jan 08; 100(1):115-23. PubMed ID: 15654790
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 08; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 8. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 9. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, Nakashima Y, Hongo M.
    Neurogastroenterol Motil; 2017 Jun 15; 29(6):. PubMed ID: 28205278
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug 15; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 11. Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study.
    Sohn W, Lee OY, Kwon JG, Park KS, Lim YJ, Kim TH, Jung SW, Kim JI.
    Neurogastroenterol Motil; 2012 Sep 15; 24(9):860-e398. PubMed ID: 22679908
    [Abstract] [Full Text] [Related]

  • 12. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ, Kunkel D, Low K, Conklin JL, Pimentel M.
    J Clin Gastroenterol; 2011 Oct 15; 45(9):790-3. PubMed ID: 21301356
    [Abstract] [Full Text] [Related]

  • 13. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A.
    Aliment Pharmacol Ther; 2011 Jun 15; 33(12):1311-21. PubMed ID: 21507028
    [Abstract] [Full Text] [Related]

  • 14. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K.
    J Gastroenterol; 2016 Sep 15; 51(9):874-82. PubMed ID: 26800997
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.
    Am J Gastroenterol; 2004 Nov 15; 99(11):2195-203. PubMed ID: 15555002
    [Abstract] [Full Text] [Related]

  • 16. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.
    Gastroenterology; 2013 Aug 15; 145(2):329-38.e1. PubMed ID: 23583433
    [Abstract] [Full Text] [Related]

  • 17. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study.
    Chapman ND, Grillage MG, Mazumder R, Atkinson SN.
    Br J Clin Pract; 1990 Nov 15; 44(11):461-6. PubMed ID: 2177997
    [Abstract] [Full Text] [Related]

  • 18. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E, Lotronex Investigator Team.
    Am J Gastroenterol; 2001 Sep 15; 96(9):2662-70. PubMed ID: 11569692
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, Lin L.
    PLoS One; 2017 Sep 15; 12(3):e0172846. PubMed ID: 28291778
    [Abstract] [Full Text] [Related]

  • 20. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 15; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.